Pharmacological therapy for acute spinal cord injury

R. John Hurlbert, Mark N. Hadley, Beverly C. Walters, Bizhan Aarabi, Sanjay S. Dhall, Daniel E. Gelb, Curtis J. Rozzelle, Timothy C. Ryken, Nicholas Theodore

Research output: Contribution to journalArticlepeer-review

232 Scopus citations


Despite 4 prospective blinded randomized controlled trials investigating the effect of MP in acute SCI, there exists no Class I medical evidence of any beneficial effect.2,4,8,20 Two prospective Class II trials also failed to demonstrate the therapeutic efficacy of MP in SCI.14,29 In total, over 980 patients have received steroids for SCI and over 280 have participated as control subjects within the protocol of a prospective clinical trial-in which, universally, all primary comparisons to establish efficacy have been negative. A variety of Class III medical evidence has been published supporting the neuroprotective effect ofMPin SCI.

Original languageEnglish (US)
Pages (from-to)93-105
Number of pages13
Issue numberSUPPL.2
StatePublished - Mar 2013


  • GM-1 ganglioside
  • Mehtylprednisolone
  • NASCIS trials
  • Pharmacologic therapy
  • Sygen trials

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology


Dive into the research topics of 'Pharmacological therapy for acute spinal cord injury'. Together they form a unique fingerprint.

Cite this